283 related articles for article (PubMed ID: 17951402)
1. Normalization of the ovarian cancer microenvironment by SPARC.
Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
3. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer.
Paley PJ; Goff BA; Gown AM; Greer BE; Sage EH
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):336-41. PubMed ID: 10985890
[TBL] [Abstract][Full Text] [Related]
4. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
[TBL] [Abstract][Full Text] [Related]
5. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
Said N; Motamed K
Am J Pathol; 2005 Dec; 167(6):1739-52. PubMed ID: 16314484
[TBL] [Abstract][Full Text] [Related]
6. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.
Stadlmann S; Amberger A; Pollheimer J; Gastl G; Offner FA; Margreiter R; Zeimet AG
Gynecol Oncol; 2005 Jun; 97(3):784-9. PubMed ID: 15943987
[TBL] [Abstract][Full Text] [Related]
7. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer.
Said N; Najwer I; Motamed K
Am J Pathol; 2007 Mar; 170(3):1054-63. PubMed ID: 17322388
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.
Belotti D; Paganoni P; Manenti L; Garofalo A; Marchini S; Taraboletti G; Giavazzi R
Cancer Res; 2003 Sep; 63(17):5224-9. PubMed ID: 14500349
[TBL] [Abstract][Full Text] [Related]
9. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer.
Brown TJ; Shaw PA; Karp X; Huynh MH; Begley H; Ringuette MJ
Gynecol Oncol; 1999 Oct; 75(1):25-33. PubMed ID: 10502421
[TBL] [Abstract][Full Text] [Related]
10. SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells.
Mok SC; Chan WY; Wong KK; Muto MG; Berkowitz RS
Oncogene; 1996 May; 12(9):1895-901. PubMed ID: 8649850
[TBL] [Abstract][Full Text] [Related]
11. The impact of the ovarian microenvironment on the anti-tumor effect of SPARC on ovarian cancer.
Greenaway JB; Koehler A; McCulloch CA; Petrik J; Brown TJ; Ringuette MJ
Biochem Cell Biol; 2012 Feb; 90(1):96-107. PubMed ID: 22003835
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
13. SPARC ameliorates ovarian cancer-associated inflammation.
Said NA; Elmarakby AA; Imig JD; Fulton DJ; Motamed K
Neoplasia; 2008 Oct; 10(10):1092-104. PubMed ID: 18813349
[TBL] [Abstract][Full Text] [Related]
14. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice.
Robinson-Smith TM; Isaacsohn I; Mercer CA; Zhou M; Van Rooijen N; Husseinzadeh N; McFarland-Mancini MM; Drew AF
Cancer Res; 2007 Jun; 67(12):5708-16. PubMed ID: 17575137
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer.
Greenaway J; Moorehead R; Shaw P; Petrik J
Gynecol Oncol; 2008 Feb; 108(2):385-94. PubMed ID: 18036641
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma.
Harlozinska A; Sedlaczek P; Kulpa J; Grybos M; Wójcik E; Van Dalen A; Einarsson R
Anticancer Res; 2004; 24(2C):1149-57. PubMed ID: 15154640
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells.
Kumar A; D'Souza SS; Nagaraj SR; Gaonkar SL; Salimath BP; Rai KM
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1221-33. PubMed ID: 19370348
[TBL] [Abstract][Full Text] [Related]
18. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
Puolakkainen PA; Brekken RA; Muneer S; Sage EH
Mol Cancer Res; 2004 Apr; 2(4):215-24. PubMed ID: 15140943
[TBL] [Abstract][Full Text] [Related]
19. SPARC enhances tumor stroma formation and prevents fibroblast activation.
Chlenski A; Guerrero LJ; Yang Q; Tian Y; Peddinti R; Salwen HR; Cohn SL
Oncogene; 2007 Jul; 26(31):4513-22. PubMed ID: 17260013
[TBL] [Abstract][Full Text] [Related]
20. Down-modulation of TNFSF15 in ovarian cancer by VEGF and MCP-1 is a pre-requisite for tumor neovascularization.
Deng W; Gu X; Lu Y; Gu C; Zheng Y; Zhang Z; Chen L; Yao Z; Li LY
Angiogenesis; 2012 Mar; 15(1):71-85. PubMed ID: 22210436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
